

A4
cont.

does not contain tyrosines or tryptophans that can add to the fluorescence and complicate the analyses. This phage was generated before we understood the importance of iron for α -synuclein biochemistry (hence, the binding site was not specifically targeted against iron binding). Even so, incubating a 10- fold excess of peptide with α -synuclein reduces iron-induced α -synuclein aggregation by 38%.

In the Claims:

A5

21. (Amended) The method of claim 20, wherein the peptide is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and MMMMRL (SEQ ID NO: 12).

22. (Amended) The method of claim 21, wherein the peptide is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and MMMMRL (SEQ ID NO: 12).

23. (Amended) The method of claim 22, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

A6

25. (Amended) The method of claim 24, whererin the agent is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and MMMMRL (SEQ ID NO: 12).

26. (Amended) The method of claim 25, wherein the agent is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and MMMMRL (SEQ ID NO: 12).

A6
cont. 27. (Amended) The method of claim 26, wherein the peptide is
SLKRLPK (SEQ ID NO: 7).

A7 35. (Amended) The composition of claim 34, wherein the
peptide is selected from the group consisting of: WRQTRKD (SEQ ID
NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ
ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK
(SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9);
HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and MMMMRL (SEQ
ID NO: 12).

36. (Amended) The composition of claim 35, wherein the
peptide is selected from the group consisting of: THRLPSR (SEQ ID
NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and MMMMRL
(SEQ ID NO: 12).

37. (Amended) The composition of claim 36, wherein the
peptide is SLKRLPK (SEQ ID NO: 7).

A8 40. (Amended) The peptide of claim 39, wherein the peptide
comprises a sequence selected from the group consisting of: WRQTRKD
(SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3);
RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO:
6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID
NO: 9); HLYHHKT (SEQ ID NO: 10); THIIHPS (SEQ ID NO: 11); and
MMMMRL (SEQ ID NO: 12).

41. (Amended) The peptide of claim 40, wherein the peptide
comprises a sequence selected from the group consisting of: THRLPSR
(SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIIHPS (SEQ ID NO: 11); and
MMMMRL (SEQ ID NO: 12).

42. (Amended) The peptide of claim 41, which comprises the
sequence SLKRLPK (SEQ ID NO: 7).
